312 related articles for article (PubMed ID: 26873692)
1. ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease.
Yassine HN; Feng Q; Chiang J; Petrosspour LM; Fonteh AN; Chui HC; Harrington MG
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873692
[TBL] [Abstract][Full Text] [Related]
2. ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease.
Marchi C; Adorni MP; Caffarra P; Ronda N; Spallazzi M; Barocco F; Galimberti D; Bernini F; Zimetti F
J Lipid Res; 2019 Aug; 60(8):1449-1456. PubMed ID: 31167810
[TBL] [Abstract][Full Text] [Related]
3. Multielectrode array analysis of cerebrospinal fluid in Alzheimer's disease versus mild cognitive impairment: a potential diagnostic and treatment biomarker.
Görtz P; Siebler M; Ihl R; Henning U; Luckhaus C; Supprian T; Lange-Asschenfeldt C
Biochem Biophys Res Commun; 2013 May; 434(2):293-7. PubMed ID: 23541573
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
5. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
7. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
Wang L;
Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
[TBL] [Abstract][Full Text] [Related]
8. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
[TBL] [Abstract][Full Text] [Related]
9. ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease.
Ko YA; Billheimer JT; Lyssenko NN; Kueider-Paisley A; Wolk DA; Arnold SE; Leung YY; Shaw LM; Trojanowski JQ; Kaddurah-Daouk RF; Kling MA; Rader DJ
Alzheimers Res Ther; 2022 Dec; 14(1):194. PubMed ID: 36572909
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.
Wang HL; Wang YY; Liu XG; Kuo SH; Liu N; Song QY; Wang MW
J Alzheimers Dis; 2016; 51(1):45-55. PubMed ID: 26836015
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
Lewczuk P; Popp J; Lelental N; Kölsch H; Maier W; Kornhuber J; Jessen F
J Alzheimers Dis; 2012; 28(1):119-25. PubMed ID: 21971403
[TBL] [Abstract][Full Text] [Related]
12. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
14. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
[TBL] [Abstract][Full Text] [Related]
15. Increased cholesterol efflux capacity in metabolic syndrome: Relation with qualitative alterations in HDL and LCAT.
Lucero D; Sviridov D; Freeman L; López GI; Fassio E; Remaley AT; Schreier L
Atherosclerosis; 2015 Sep; 242(1):236-42. PubMed ID: 26232163
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
17. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
19. Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease.
Agosta F; Dalla Libera D; Spinelli EG; Finardi A; Canu E; Bergami A; Bocchio Chiavetto L; Baronio M; Comi G; Martino G; Matteoli M; Magnani G; Verderio C; Furlan R
Ann Neurol; 2014 Dec; 76(6):813-25. PubMed ID: 25087695
[TBL] [Abstract][Full Text] [Related]
20. Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease.
Cipollari E; Szapary HJ; Picataggi A; Billheimer JT; Lyssenko CA; Ying GS; Shaw LM; Kling MA; Kaddurah-Daouk R; Rader DJ; Praticò D; Lyssenko NN;
J Alzheimers Dis; 2020; 74(2):563-578. PubMed ID: 32065798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
